CCR7

Chr 17

C-C motif chemokine receptor 7

Also known as: BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7, EBI1

NCBI Gene: 1236ENSG00000126353UniProt: P32248

The protein encoded by this gene is a member of the G protein-coupled receptor family. This receptor was identified as a gene induced by the Epstein-Barr virus (EBV), and is thought to be a mediator of EBV effects on B lymphocytes. This receptor is expressed in various lymphoid tissues and activates B and T lymphocytes. It has been shown to control the migration of memory T cells to inflamed tissues, as well as stimulate dendritic cell maturation. The chemokine (C-C motif) ligand 19 (CCL19/ECL) has been reported to be a specific ligand of this receptor. Signals mediated by this receptor regulate T cell homeostasis in lymph nodes, and may also function in the activation and polarization of T cells, and in chronic inflammation pathogenesis. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Sep 2014]

6
Active trials
42
ClinVar variants
8
Pathogenic / LP
2.2
Missense Z
0.78
LOEUF
12
Pubs (2 yr)
Clinical Summary— CCR7
⚡
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.34) despite low pLI — interpret in context.
📋
ClinVar Variants
8 Pathogenic / Likely Pathogenic· 31 VUS of 42 total submissions
💊
Clinical Trials
6 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)

pubtator: Error: PubTator3 HTTP 502

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.78LOEUF
pLI 0.058
Z-score 2.10
OE 0.34 (0.17–0.78)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.18Z-score
OE missense 0.61 (0.53–0.70)
149 obs / 244.9 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.34 (0.17–0.78)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.61 (0.53–0.70)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.01
0≤1.21.6
LoF obs/exp: 4 / 11.8Missense obs/exp: 149 / 244.9Syn Z: -0.06

ClinVar Variant Classifications

42 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic8
VUS31
Likely Benign2
Benign1
8
Pathogenic
31
VUS
2
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
8
0
8
Likely Pathogenic
0
0
0
0
0
VUS
0
31
0
0
31
Likely Benign
0
1
1
0
2
Benign
0
0
0
1
1
Total0329142

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CCR7 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis.
MacDonald L et al.·Immunity
2024
Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.
Barcia Durán JG et al.·Nat Cardiovasc Res
2024
CAR-T cell expansion platforms yield distinct T cell differentiation states.
Song HW et al.·Cytotherapy
2024
OMIP-099: 31-color spectral flow cytometry panel to investigate the steady-state phenotype of human T cells.
Zacharias ZR et al.·Cytometry A
2024
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.
Cieri N et al.·Blood
2013
CCR7(+) dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse.
Sun Y et al.·Nat Commun
2025
CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
Hirth M et al.·Gastroenterology
2020Cohort
Single-cell RNA sequencing of chronic idiopathic erythroderma defines disease-specific markers.
Chennareddy S et al.·J Allergy Clin Immunol
2025
Distinct mural cells and fibroblasts promote pathogenic plasma cell accumulation in idiopathic pulmonary fibrosis.
Yang Z et al.·Eur Respir J
2025
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
Roberts EW et al.·Cancer Cell
2016
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Engineered CCR7 overexpression enhances nodal CAR-T cell homing and cytotoxicity toward B cell lymphoma.
Zschummel M et al.·Cancer Immunol Res
2026
miR-31-modified bone marrow mesenchymal stem cells facilitate autophagic cell death of colorectal cancer via binding to CCR7 to modulate PI3K/Akt/mTOR signals.
Zhang W et al.·Pak J Pharm Sci
2026
Bulk and Single-Cell Transcriptomics Reveal That SCO2 Drives Psoriasis via Activating CCR7+ Dendritic Cell.
Chen D et al.·Int J Mol Sci
2026Open Access
CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21.
Bahng I.·Front Immunol
2026Open Access
Mesenchymal Stem Cells Restore Endometrial Integrity and Sustain Pregnancy via CCR7-ERK/JNK Signaling Modulation.
Lei Y et al.·Stem Cells Int
2026Open Access
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Biliary Tract CancerColorectal CarcinomaGastric Cancer, Metastatic

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

RECRUITING
NCT06937567Phase EARLY_PHASE1Zhejiang UniversityStarted 2024-12-26
CDH17 CAR-T
Familial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)

Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced Ex Vivo with the UNC13D LV Vector Expressing the UNC13D CDNA

NOT YET RECRUITING
NCT06736080Phase PHASE1, PHASE2Assistance Publique - Hôpitaux de ParisStarted 2025-01
MUNC-CD34MUNC-T3
Platinum-Resistant Ovarian Carcinoma

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

RECRUITING
NCT05225363Phase PHASE1City of Hope Medical CenterStarted 2022-05-05
Chimeric Antigen Receptor T-cellsCyclophosphamideFludarabine
AutophagyGalectinsHIV Infections

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

RECRUITING
NCT04160455Centre Hospitalier Régional d'OrléansStarted 2019-11-07
expression of a panel
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

RECRUITING
NCT05071222Phase PHASE1, PHASE2Assistance Publique - Hôpitaux de ParisStarted 2023-07-19
ARTEGENE drug product
Bladder Cancer

Antitumor T Cell Responses in Patients With Bladder Cancer

NOT YET RECRUITING
NCT06334406Centre Hospitalier Universitaire de BesanconStarted 2024-04-02
Biological samples

External Resources

Links to major genomics databases and tools

Franklin by Genoox
AI-powered variant curation and clinical analysis
DECIPHER
Genomic variants and phenotypes in rare disease patients